- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | ASCO: Actuate's pancreatic cancer drug boosts survival by 3 months in phase 2 study | ||
| Mo | ASCO: AstraZeneca's oral SERD tied to 56% PFS benefit in phase 3 breast cancer trial | ||
| Mo | J&J shares survival data on prostate cancer bispecific, furthering broad but solitary pursuit of KLK2 | ||
| So | ASCO: Bicara ties antibody to 46% 2-year survival rate for head and neck cancer subset | ||
| 30.05. | Merck plays lion tamer, taking middle dose of ROR ADC forward in relapsed or refractory DLBCL | ||
| 30.05. | Sanofi, Regeneron's IL-33 drug fails one of 2 COPD studies as FDA timeline thrown in doubt | ||
| 30.05. | Roche links BTK inhibitor to low relapse rate across 96-week multiple sclerosis trial | ||
| 29.05. | 'Hanging on by our fingernails': Stealth CEO questions efficiency behind FDA rejection of rare disease drug | ||
| 29.05. | Keros culls PAH asset, prompting layoffs for 70 workers | ||
| 29.05. | Intellia's stock sinks on gene therapy patient's raised enzyme levels, but analysts keep faith | ||
| 29.05. | Stealth hit by FDA rejection to twice-delayed filing as it lays off staff | ||
| 29.05. | HHS axes Moderna's $590M pandemic bird flu vaccine contract, ending funding for late-phase trials | ||
| 28.05. | Adios, iTeos: Biotech folds weeks after GSK TIGIT termination | ||
| 28.05. | Merck KGaA shares phase 3 rare tumor data ahead of showdown with Daiichi and Ono | ||
| 28.05. | GSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 win | ||
| 27.05. | 5 people charged in $600K insider trading scheme tied to Novartis' Chinook acquisition: DOJ | ||
| 27.05. | Eli Lilly lands next-gen pain asset in SiteOne Therapeutics acquisition worth up to $1B | ||
| 27.05. | Gilgamesh links psychedelic to 90% remission rate in midphase depression trial | ||
| 27.05. | Biogen maps out $1B biobucks deal with RNAi-focused City Therapeutics | ||
| 27.05. | Rocket crashes as gene therapy patient dies, FDA imposes hold | ||
| 27.05. | Boundless Bio lays off 33% of staff as lead program stumbles | ||
| 27.05. | Prothena reburies drug after second swing at rare disease misses, plans 'substantial' layoffs | ||
| 23.05. | Endometrial cancer data on Genmab's Elahere rival beat forecast, fueling push into phase 3 | ||
| 23.05. | Merus hails 'unprecedented' survival on solid tumor bispecific, sparking stock jump | ||
| 23.05. | ASCO: Innate claims long-term lymphoma data show 'sustained effect' of anti-KIR3DL2 antibody |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .